- Home
- CABA
CABA
Cabaletta Bio Inc.
as 07-26-2024 4:00pm EST
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 491.9M | IPO Year: | 2019 |
| Target Price: | $35.78 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.71 - $26.35 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cabaletta Bio Inc. (CABA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Binder Gwendolyn | CABA | See Remarks | Jan 19 '24 | Sell | $19.54 | 10,300 | $201,210.50 | 20,700 | SEC Form 4 |
| Binder Gwendolyn | CABA | See Remarks | Jan 19 '24 | Sell | $20.33 | 700 | $14,228.62 | 20,000 | SEC Form 4 |
| Binder Gwendolyn | CABA | See Remarks | Dec 19 '23 | Sell | $21.76 | 7,868 | $171,195.88 | 23,132 | SEC Form 4 |
| Binder Gwendolyn | CABA | See Remarks | Dec 19 '23 | Sell | $22.22 | 3,132 | $69,593.35 | 20,000 | SEC Form 4 |
Latest Cabaletta Bio Inc. News
CABA Breaking Stock News: Dive into CABA Ticker-Specific Updates for Smart Investing
Insider Monkey
18 days ago
Cabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock Right Now?
GlobeNewswire
24 days ago
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
MT Newswires
a month ago
Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday
MT Newswires
a month ago
Sector Update: Health Care
MT Newswires
a month ago
Cabaletta Bio Says Autoimmune Disease Therapy Showed Promise in Early Results
GlobeNewswire
a month ago
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
GlobeNewswire
2 months ago
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
Simply Wall St.
2 months ago
We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth
Compare CABA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CABA Cabaletta Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.